Dechra Pharmaceuticals PLC (LON:DPH – Get Rating)’s share price hit a new 52-week low on Monday . The company traded as low as GBX 2,473.32 ($30.14) and last traded at GBX 2,480 ($30.23), with a volume of 64999 shares. The stock had previously closed at GBX 2,574 ($31.37).
Analyst Ratings Changes
A number of research firms recently issued reports on DPH. Jefferies Financial Group restated a “buy” rating and set a GBX 3,112 ($37.93) price objective on shares of Dechra Pharmaceuticals in a research report on Tuesday, February 28th. Berenberg Bank reissued a “hold” rating and set a GBX 2,850 ($34.73) price target on shares of Dechra Pharmaceuticals in a report on Monday, February 27th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Dechra Pharmaceuticals from GBX 4,600 ($56.06) to GBX 4,000 ($48.75) and set an “overweight” rating on the stock in a report on Tuesday, March 7th.
Dechra Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 60.73, a quick ratio of 1.66 and a current ratio of 2.73. The firm has a market capitalization of £2.95 billion, a P/E ratio of 7,377.14, a price-to-earnings-growth ratio of 1.42 and a beta of 0.71. The business has a fifty day moving average of GBX 2,867.69 and a 200-day moving average of GBX 2,819.92.
Dechra Pharmaceuticals Cuts Dividend
About Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.